Skip to main content
Contact Us
Subscribe
E-Edition
83°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Genmab A/S ADR
(NQ:
GMAB
)
28.81
+0.01 (+0.03%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Genmab A/S ADR
< Previous
1
2
3
4
5
Next >
United Airlines, Interactive Brokers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
October 18, 2023
U.S. stock futures traded lower this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
What 13 Analyst Ratings Have To Say About Genmab
October 13, 2023
Via
Benzinga
Expert Ratings for Genmab
September 26, 2023
Via
Benzinga
Don’t Miss the Boom: 3 Biotech Stocks Set to Explode Higher
September 26, 2023
With their seamless blend of promise and innovation, these biotech stocks to buy offer a strategic gateway to fortify your portfolio.
Via
InvestorPlace
Why Shares of Iovance Biotherapeutics Dropped Thursday
September 14, 2023
The biotech stock's lead therapy is looking at some competition.
Via
The Motley Fool
AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst
September 11, 2023
On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line treatment for patients
Via
Benzinga
Analyst Expectations for Genmab's Future
September 05, 2023
Via
Benzinga
Analyst Expectations for Genmab's Future
August 15, 2023
Via
Benzinga
12 Analysts Have This to Say About Genmab
July 24, 2023
Via
Benzinga
Why Shares of Zai Lab Limited Were Jumping on Tuesday
September 05, 2023
Zai Lab's shares benefited from positive clinical trial news.
Via
The Motley Fool
Encouraging Data From Seagen/Genmab's Cervical Cancer Study - Tivdak Success Sets Stage For New Indications
September 05, 2023
Seagen Inc (NASDAQ: SGEN) and Genmab A/S (NASDAQ: GMAB) released topline data from the Phase 3 innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on...
Via
Benzinga
The 3 Most Promising Biotech Stocks to Own Now
August 31, 2023
These top biotech stock picks with high and leading growth potential are must-owns for investors looking for high upside potential.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2023
August 24, 2023
Via
Benzinga
Where Genmab Stands With Analysts
June 26, 2023
Via
Benzinga
Expert Ratings for Genmab
June 06, 2023
Via
Benzinga
Recap: Genmab Q1 Earnings
May 10, 2023
Via
Benzinga
How To Attend Genmab Q1 2023 Earnings Conference Call
May 08, 2023
Via
Benzinga
Is AbbVie Still a Good Dividend Stock to Buy?
August 08, 2023
Find out if AbbVie can overcome sinking sales of its top-selling product.
Via
The Motley Fool
3 Things About Johnson & Johnson Every Smart Investor Knows
July 28, 2023
The company has been a strong value stock but faces big changes this year.
Via
The Motley Fool
3 Biotech Stocks You Better Be Buying on Each and Every Dip
July 27, 2023
Biotech companies can bring about life-changing innovations. We've created a list to help you find the best biotech stocks out there.
Via
InvestorPlace
3 Biotech Stocks That AI is Loving in July
July 12, 2023
As AI becomes a more entrenched aspect of society, investors can lean on these AI recommended biotech stocks with predicted high potential.
Via
InvestorPlace
Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators?
July 02, 2023
In May, the FDA approved epcoritamab, developed by AbbVie and Genmab, as a treatment for a type of blood cancer.
Via
The Motley Fool
Price Over Earnings Overview: Genmab
April 27, 2023
Via
Benzinga
Analyst Ratings for Genmab
April 20, 2023
Via
Benzinga
P/E Ratio Insights for Genmab
April 11, 2023
Via
Benzinga
This Foreboding Sign Looms Over Genmab's Chart
March 31, 2023
Via
Benzinga
Genmab/AbbVie's Blood Cancer Treatment Shows 82% Response Rate In Pretreated Follicular Lymphoma Patients
June 28, 2023
Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV) have announced topline results from the follicular lymphoma (FL) cohort of the phase 1/2 EPCORE NHL-1 clinical trial evaluating epcoritamab...
Via
Benzinga
FDA Approves AbbVie/Genmab's Cancer Drug As First Bispecific Antibody For Type Of Lymphoma In Adult Patients
May 19, 2023
The FDA has approved Epkinly (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)...
Via
Benzinga
Focus On Genmab's Pipeline If Darzalex Arbitration with Janssen Goes Sideways: Analyst
April 24, 2023
Via
Benzinga
Genmab Stock Hits 80-Plus Relative Strength Rating Benchmark
April 17, 2023
On Monday, Genmab stock saw its Relative Strength (RS) Rating jump into the 80-plus percentile, rising to 84, up from 80 the day before.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.